Mersana

Closed

Cambridge, United States · Founded 2001 · $103.0M raised

Employees
51–200
Founded
2001
Business Model
B2B
Total Funding
$103.0M
Last Round
$33.0M Series CJun 2016
Rounds
5

About

Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugates (ADCs) for cancer treatment, using its proprietary Dolasynthen and Immunosynthen ADC platforms. The company developed Emi-Le (emiltatug ledadotin), targeting B7-H4, for triple-negative breast cancer and other rare cancers. Mersana was acquired by Day One Biopharmaceuticals in January 2026.

Summary

Mersana is a Biotech company based in Cambridge, United States, founded in 2001. It has raised $103.0M in total across 5 rounds, most recently a $33.0M Series C round in Jun 2016. Investors include Wellington Management, New Enterprise Associates and Pfizer Ventures.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJun 2017
$75.0M

Sign up to see all 6 rounds

Venture Round through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Mersana on Indexed.vc
<a href="https://indexed.vc/companies/mersana"><img src="https://indexed.vc/api/badge/company/mersana" alt="Mersana on Indexed.vc" width="260" height="76" /></a>